- Home
- LPTX vs ATOS Comparison
LPTX vs ATOS Comparison
Compare LPTX & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- ATOS
- Stock Information
- Founded
- LPTX 2011
- ATOS 2009
- Country
- LPTX United States
- ATOS United States
- Employees
- LPTX N/A
- ATOS N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- LPTX Health Care
- ATOS Health Care
- Exchange
- LPTX Nasdaq
- ATOS Nasdaq
- Market Cap
- LPTX 119.6M
- ATOS 112.5M
- IPO Year
- LPTX N/A
- ATOS 2012
- Fundamental
- Price
- LPTX $0.38
- ATOS $0.78
- Analyst Decision
- LPTX Buy
- ATOS Strong Buy
- Analyst Count
- LPTX 2
- ATOS 3
- Target Price
- LPTX $8.00
- ATOS $7.13
- AVG Volume (30 Days)
- LPTX 283.3K
- ATOS 729.3K
- Earning Date
- LPTX 05-13-2025
- ATOS 05-13-2025
- Dividend Yield
- LPTX N/A
- ATOS N/A
- EPS Growth
- LPTX N/A
- ATOS N/A
- EPS
- LPTX N/A
- ATOS N/A
- Revenue
- LPTX N/A
- ATOS N/A
- Revenue This Year
- LPTX N/A
- ATOS N/A
- Revenue Next Year
- LPTX N/A
- ATOS N/A
- P/E Ratio
- LPTX N/A
- ATOS N/A
- Revenue Growth
- LPTX N/A
- ATOS N/A
- 52 Week Low
- LPTX $0.22
- ATOS $0.55
- 52 Week High
- LPTX $4.79
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- LPTX 48.68
- ATOS 44.02
- Support Level
- LPTX $0.35
- ATOS $0.78
- Resistance Level
- LPTX $0.40
- ATOS $1.07
- Average True Range (ATR)
- LPTX 0.04
- ATOS 0.07
- MACD
- LPTX 0.00
- ATOS -0.02
- Stochastic Oscillator
- LPTX 53.70
- ATOS 13.80
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.